A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Regular and Young Investigator Award Abstracts
or INTASYL 27790 at two dose concentrations were administered IT; anti-CTLA-4 monoclonal antibody (mAb; clone 9D9) was administered intraperitoneally (IP). Tumor volumes and body weights were recorded longitudinally. Results mCTLA-4-targeting INTASYL 27790 provided concentration-associated silencing of mCTLA-4 in vitro. When administered IT, mCTLA-4-targeting INTASYL 27790 elicited robust dose-associated antitumor efficacy in both in vivo tumor models compared with vehicle-or NTC-treateddoi:10.1136/jitc-2022-sitc2022.0537 fatcat:3lancfhed5emjky2sr7yesjz54